Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36792 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 98-0373793 (State or other jurisdiction of (I.R.S. Employer ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-36792 (Nasdaq Capital Market) Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-kn ...

Cytosorbents Corporation (NASDAQ:CTSO) Q4 2021 Earnings Conference Call March 8, 2022 4:30 PM ET Company Participants Terri Anne Powers - Vice President, Investor Relations and Corporate Communications Phillip Chan - Chief Executive Officer Vincent Capponi - President and Chief Operating Officer Kathleen Bloch - Chief Financial Officer Efthymios Deliargyris - Chief Medical Officer Christian Steiner - Executive Vice President, Sales and Marketing and Managing Director, CytoSorbents Europe Christopher Cramer ...

HELPING TO TREAT INFLAMMATION AND DEADLY CONDITIONS IN INTENSIVE CARE AND CARDIAC SURGERY CytoSorbents Corporation - NASDAQ: CTSO SVB Leerink Global Healthcare Conference – February 2022 Safe Harbor Statement This presentation contains "forward-looking statements" pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or ach ...

CytoSorbents Corporation (NASDAQ:CTSO) Q3 2021 Earnings Conference Call November 4, 2021 4:30 PM ET Company Participants Terri Powers - VP of IR & Corporate Communications Phillip Chan - CEO Christian Steiner - EVP of Sales & Marketing Efthymios Deliargyris - Chief Medical Officer Kathy Bloch - CFO Conference Call Participants Priya Sachdeva - SVB Leerink Bryan Bergin - Cowen Operator Good afternoon. And welcome to the CytoSorbents' Third Quarter 2021 Financial and Operating Results Conference Call. At thi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36792 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 98-0373793 (State or other jurisdiction of (I.R.S. Empl ...

CytoSorbents Corporation (NASDAQ:CTSO) Q2 2021 Earnings Conference Call August 3, 2021 4:30 PM ET Company Participants Terri Anne Powers - VP, IR and Corporate Communications Phillip Chan - Chief Executive Officer Efthymios Deliargyris - Chief Medical Officer Kathleen Bloch - Chief Financial Officer Christian Steiner - Executive Vice President, Sales and Marketing, Managing Director, CytoSorbents Europe GmbH Conference Call Participants Danielle Antalffy - SVB Leerink Anthony Petrone - Jefferies Andrew D'Si ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36792 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 98-0373793 (State or other jurisdiction of (I.R.S. Employer ...

CytoSorbents Corporation (NASDAQ:CTSO) Q1 2021 Earnings Conference Call May 4, 2021 4:45 PM ET Company Participants Amy Vogel - Investor Relations Phillip Chan - Chief Executive Officer Efthymios Deliargyris - Chief Medical Officer Kathleen Bloch - Chief Financial Officer Christian Steiner - Executive Vice President, Sales and Marketing, Managing Director, CytoSorbents Europe GmbH Conference Call Participants Anthony Petrone - Jefferies Josh Jennings - Cowen Danielle Antalffy - SVB Leerink Andrew D'Silva - ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36792 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) 98-0373793 (State or other jurisdiction of (I.R.S. Employer Identifi ...